Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ( Kadmon or the Company ) (NASDAQ: KDMN) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-01797, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Kadmon securities between October 1, 2020 and March 10, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch
Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch
JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal product candidate for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. The New Drug Application (NDA) for Brexafemme is under review
Search jobs 10-May-2021 Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™
Strengthened balance sheet with $110M in cash and cash equivalents as of March 31, 2021
Company remains on track for potential approval in the US in August 2021 and in Europe in early 2022
Company to host conference call at 8am ET
CAMBRIDGE, Mass. (BUSINESS WIRE)
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2021. The Company’s Biologics License Application (BLA) for the Company’s lead program, Vicineum, is currently under Priority Review with the Food and Drug Administration (FDA) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with a target Prescription Drug User Fee Act (PDUFA) da
Published: May 10, 2021
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE)
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2021.
“We continued to make significant strides in the quarter toward becoming a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with serious CNS conditions. We successfully filed our NDA for AXS-05 for the treatment of MDD with the FDA, which was granted Priority Review, and are on track to file our NDA for AXS-07 for the acute treatment of migraine this quarter,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Pre-commercial activities are intensifying as planned to ensure launch readiness assuming FDA approval. The rest of our pipeline continues to progress with the anticipated initiation of the plann
AXS-07 for migraine, NDA submission (2Q 2021)
AXS-05 for smoking cessation, FDA meeting (3Q 2021)
AXS-05 for MDD, commercial launch, if approved (2H 2021)
Clinical Trial Readouts:
Clinical Trial Initiations:
Upcoming Scientific Conferences
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting, May 17-20, 2021
American Society for Clinical Psychopharmacology (ASCP) annual meeting, June 1-4, 2021
American Headache Society (AHS) annual meeting, June 3-6, 2021
Upcoming Investor Conferences
BofA Health Care Conference, May 11, 2021 (to be webcast)
RBC Capital Markets Global Healthcare Conference, May 18, 2021 (to be webcast)
UBS Global Healthcare Virtual Conference, May 24, 2021 (to be webcast)
William Blair Growth Stock Conference, June 3, 2021 (to be webcast)
First Quarter 2021 Financial Results